13th Annual Outsourcing in Clinical Trials Nordics 2025

The annual meeting place for pharmaceutical, biotechnology, and medical device communities in the Nordics to network and discuss strategies for operational success in clinical trials

21 - 22

October

2025
  • Clarion Hotel & Congress Copenhagen Airport, Denmark
  • Complimentary
  • Why attend?
  • 2024 Agenda
  • OCT Advisory Board
  • 2024 Speakers
  • Plan Your Visit
  • Event Gallery
  • Sponsors
  • Media Centre
  • Why partner?
  • Contact Us
close

Featured Speakers

Back

Lene Grejs Petersen​

Senior Advisor, Danish Medicines Agency

Lene Grejs Petersen is Senior Adviser at the Danish Medicines Agency, Clinical Trial Unit. Lene is member of the Clinical Trials Coordinating and Facilitation Group (CTCG) member since 2008 and is the Danish representative Clinical Trials Advisory Group (CTAG) since 2022. Lene has been an employee at the Danish Medicines Agency since 2000 and she has been involved in the implementation of the EU Clinical Trials Regulation and works as a regulatory assessor and coordinator of clinical trials. Lene has a background as Master in Pharmacy.

Next speaker
Back

Stephen Lutsch​

Senior Director Clinical Trial Digital Innovation, Genmab

In my position as Senior Director - Clinical Trial Digital Innovation at Genmab, I lead a team driving AI adoption within clinical operations, decentralized clinical trials and digital innovation in drug development. Previously, I have been working to bring the best disruptive innovation into normal clinical operations at LEO Pharma to help improve and accelerate their clinical trials. Furthermore, I am trying to solve some of the toughest challenges related to scaling digitalization, data, and automation to generate competitive advantages across business units. One aspect is driving the necessary foundational components around a scalable GxP data platform, machine learning opportunities as well as automating digital processes with robotics process automation. Besides leading the necessary change internally, focus is on a design-thinking approach where we put the patient and site at the center. I have an ambition towards “delighting” patients, investigators, and sponsors by solving the real-world challenges they face by leveraging both qualitative interviews and observation, as well as quantitative methods to reveal actionable insights

Next speaker
Back

Morten Pedersen​

VP, Head of Clinical Operations, Lundbeck

Morten completed his Master’s degree in Biotechnology at National University of Ireland, Galway, in 1997, specializing in Pharmacology. He joined Lundbeck in August 2020 as VP, Head of Clinical Operations.

Career to date Morten started at a CRO in 1997 as a CRA on an Epilepsy study.  In the subsequent years he worked in CRO’s, consultancy and big Pharma taking on roles within Project Management, Program Oversight, Innovation and Strategic Partnerships.  He joined Pfizer in 2003 and has a wide range of project management experience delivering projects across multiple therapeutic areas. From 2007 to 2011 he held a leadership role in Pfizer’s Clinical Study Management group providing Operational Oversight in various outsourcing models.  As Group Lead of Emerging Markets and Established Products Business Units he managed a team of Program Directors in a variety of Therapy Areas from Phase II to Late Phase and Non-Interventional trials. From late 2011 Morten joined an Innovation technology CRO in the role of Senior Director and Head of Strategic Partnerships with the aim of improving Clinical Trial efficiencies and supporting Trial Sites. In August 2016 he joined InVentiv Health as VP, Head of Program Delivery in Neuroscience, before the group merged with INC to become Syneos Health.

 

Next speaker
Back

Helen Johansen Blanco​

Chief Operating Officer, Node Pharma A/S

Helén Johansen Blanco has 24 years of clinical development experience, managing Phase I to III clinical trials leading to the successful launch of several oncology products, as Revlimid, Xofigo and a Herceptin biosimilar. She has experience in project management and financial oversight of large global clinical trials conducted in all continents of the world, mainly within oncology, but also therapeutic areas as cardiovascular and gastrointestinal. Mrs. Blanco has previously worked for large international pharma companies such as AstraZeneca and Mylan, as well as small, medium to large sized biotechnology companies as Nordic Nanovector, Oncoinvent, Cantargia, Cytovation and Celgene. Currently she holds a position as Chief Operating Officer at Node Pharma AS, a small medium sized Norwegian biotech company. She holds a Diploma Engineer/MSc degree in Biophysics and medical technology and a MBA.

Next speaker
Back

Magnus Jörntén-Karlsson​

Head of Digital Patient & Site Technology, Evinova at AstraZeneca

Next speaker
Back

Caroline Sandstroem​

Head of Global Clinical Quality, Ferring Pharmaceuticals

Dr. Caroline Sandström received her PhD in Medical Science from Lund University, Sweden in 2008. She has then worked for Novo Nordisk A/S, Denmark for several years as a pharmacologist driving and executing pharmacological plans supporting pre-clinical projects.

Her interest and enthusiasm for project management, continuous improvement, streamlining initiatives and training was then later beneficially used when she moved into the compliance area managing global improvement and training initiatives within R&D Quality Management System (QMS) including Clinical. For example, she was the project manager for implementing the effective use of Root Cause Analysis in Clinical Development activities but also being highly involved in initiatives related to Quality Culture.  Ferring Pharmaceuticals A/S in Copenhagen, DK. On a daily basis she was involved in discussing, driving compliance and improvement initiatives within both Non-Clinical, Clinical and Pharmacovigilance related activities. She has taken a very active role in contributing to a collaborative and transparent organization where sharing learnings are a main focus area.

From beginning of May 2022, she moved into the position of being Head of the Global Clinical Quality Department being responsible for the QA support of global key stakeholder areas such as Clinical Development, Regulatory Affairs, Pharmacovigilance and Discovery. Her scientifically driven problem-solving skills are used for implementing global cross-functional initiatives, and for supporting and strengthening the harmonization and quality mindset in the organization.

Next speaker
Back

Joachim Lovin​

DCT Specialist, Novo Nordisk

Joachim Lövin has worked in the pharmaceutical industry for over 20 years across various therapeutic areas and organizations. During this time, Joachim has worked in different roles spanning over Data Management, Project Management, Process Development, Senior Business Analyst and Clinical Operations. In his current role as DCT Specialist, Joachim focuses on supporting trials including competence development of Clinical Operations, identifying opportunities, and operationalising Decentralised Clinical Trial Elements across Novo Nordisk. Joachim is the Workstream Lead for the Modernizing Clinical Trial Conduct workstream for TransCelerate Biopharma, and a member of the eClinical Forums Trial of the Future. All of Joachim’s work is aligned with his passion to improve patient experience and accelerating clinical trials.

2025 Sponsors Included:

Back

Company Information

ARENSIA Exploratory Medicine, a German-based company, is a leader in “first-in-patient” Phase IB and II/Proof-of-Concept clinical trials across a wide range of disease areas. With 14 proprietary research clinics and cutting-edge Phase I infrastructure, ARENSIA accelerates the early detection of efficacy signals for new therapies at an unparalleled speed. Its streamlined, highly efficient approach reduces patient recruitment time and costs by over 50% compared to conventional trial sites, which are often overcrowded and understaffed. This exceptional performance has resulted in a 93% repeat business rate and robust growth through collaborations with top pharmaceutical companies, biotechs, and global CROs. Headquartered in Düsseldorf, ARENSIA operates with a team of 600 professionals across 8 countries.

Company Website

To learn more, please visit our website - http://www.arensia-em.com/

Next Sponsor
Back

Company Information

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 35,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

Company Website

To learn more, please visit our website - https://www.medidata.com

Next Sponsor
Back

Company Information

Fortrea is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Company Website

To learn more, please visit our website - https://www.fortrea.com/

Next Sponsor
Back

Company Information

TFS HealthScience is a global Contract Research Organization (CRO) partnering with biotechnology and pharmaceutical companies throughout their entire clinical development journey. Bringing together nearly 700 professionals, we deliver tailored clinical research services in more than 40 countries. TFS supports customers with comprehensive solutions including full clinical development services, strategic and flexible resourcing. In partnership, we build solution-driven teams of experienced professionals working together for a healthier future. Our mission is to bring treatments to patients faster. For more information, please visit www.tfscro.com.

Company Website

To learn more, please visit our website - www.tfscro.com.

Next Sponsor
Back

Company Information

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development. With deep therapeutic and regulatory expertise and an expansive global footprint across the Asia-Pacific region, North America, and Europe, Novotech offers clients an accelerated path to bring life-changing therapies to market.

Company Website

To learn more, please visit our website - www.novotech-cro.com

    Why attend?

    This is the unmissable event that the pharmaceutical, biotechnology, and medical device communities need to come together and discuss strategies for operational success in clinical trials. Combining our OCT, CTS and Medical Devices events, this is the perfect platform for professionals from across a range of clinical trial functions to meet, network, and hear about latest developments

     

    WHAT TO EXPECT FOR 2025?

    200+

    Attendees

    		30+

    Exhibitors

    		30+

    Speakers
    200+

    Attendees

    		30+

    Exhibitors
    30+

    Speakers

    Testimonials

    One of the best conferences I have attended. A good mix of suppliers and great speakers that talked about relevant subjects.

    AQILION AB

    Thank you for a great conference! Very inspiring and very well conducted.

    Bavarian-nordic

    See What It's All About

    2024 Agenda

    • 1 Oct 2024
    • 2 Oct 2024
    Expand All

    Streams

    Stream one

    OUTSOURCING IN CLINICAL TRIALS & CLINICAL OPERATIONS

    7:30 AM

    Registration and refreshments

    8:15 AM

    Chairperson’s opening remarks

    Speakers

    Helen Johansen Blanco
    Chief Operating Officer, Node Pharma A/S

    8:30 AM

    Sharing latest updates to the Clinical Trial Regulation (CTR) and Clinical Trial Information System (CTIS)

    • Providing latest updates: what’s new from the EU regulatory framework?
    • Learning from previous submissions: tips and tricks

    Speakers

    Lene Grejs Petersen
    Senior Advisor, Danish Medicines Agency

    9 AM

    A new paradigm for clinical innovation

    The clinical research industry is at an inflection point. Advancements in technology have created the opportunity to transform clinical trial outcomes, but to make this ambition a reality, we must now rethink how we engage with patients.

    Today, we often treat patient relationships as transactional, de-identified numbers on individual clinical trials. We need a new way of thinking about patients. A more longitudinal way, with greater pre-trial engagement and post-trial follow-up, and across multiple studies and healthcare experiences.

    We also need to change how we look at patient data, widening the lens to understand patients’ health and research journeys across a broad ecosystem of data sources. But how do we execute this paradigm shift when we’re also under pressure to accelerate timelines, reduce risk, lower costs, and improve quality?

    In this presentation, we’ll explore:

    • Industry drivers of this clinical research evolution
    • Challenges faced & the value of change
    • Reasons to believe - Improving trial experiences for patients, sites, CROs, & sponsors

    Speakers

    Richard Gray
    Managing Partner, Medidata, Dassault Systemes

    9:30 AM

    Building an Outsourcing Strategy for your clinical trials

    • Initiation: landscaping and defining the project
    • Strategy development: analyses and stakeholder management
    • Implementation: selecting vendors, training and alignment
    • Maintenance: KPIs and governance
    • Tips and tricks to consider

    Speakers

    Rikke Winther
    Outsourcing Specialist, Camurus AB

    Streams

    Stream one

    OUTSOURCING IN CLINICAL TRIALS & CLINICAL OPERATIONS

    Stream two

    CLINICAL TRIALS TECHNOLOGY & INNOVATION

    8:15 AM

    Registration and refreshments

    8:45 AM

    Chairperson’s Opening Remarks

    Speakers

    Helen Johansen Blanco
    Chief Operating Officer, Node Pharma A/S

    9 AM

    Navigating through the jungle of regulatory requirements for combination trials

    • Overview of the COMBINE project created to analyse challenges and find solutions for combined studies
    • Reviewing key regulatory factors within CTR, MDR and IVD to ensure compliance
    • Best practice for streamlining your submissions to optimise approvals for parallel submissions

    Speakers

    Ditte Zerlang Andersen
    Senior EU Project Lead, Senior Adviser, Danish Medicines Agency

    9:30 AM

    Asia Pacific clinical trials: opportunities and regulatory updates

    • Advantages in running clinical trials in the APAC region
    • Key country differences and regulatory updates
    • How to overcome challenges to ensure clinical trial success

    Speakers

    Kento Nakamura
    Strategy and Corporate Development, CMIC

    10 AM

    Improving sustainability: Healthcare transition into a Net Zero world

    • Healthcare sector’s responsibility and action to address the climate crisis as accelerator for the health crisis
    • Clinical best-practices to save significant natural and financial resources
    • Progress to date and influencing sourcing services

    Speakers

    Morten Pedersen
    VP, Head of Clinical Operations, Lundbeck

    10:30 AM

    Morning Refreshments & Networking

    11 AM

    Re-evaluating your study if things go wrong in clinical trial: to stay or change?

    • Pro-actively preparing for the worst up front
    • Considerations for changing or re-assessing sites
    • Assessing, selecting and switching vendors: benefits and challenges
    • Case study example: success and lessons learnt

    Speakers

    Helen Johansen Blanco
    Chief Operating Officer, Node Pharma A/S

    11:30 AM

    Reimagining clinical trials: Boosting efficiency with simplified, low-code builds

    • In clinical trials where approval is always tomorrow and go-live is yesterday, use of innovative technology is critical to saving time and boosting efficiency but doesn't have to
      introduce complexity
    • A simplified study build process relies on reuse such as pre-made form libraries and duplication of previous studies
    • Time reductions in study build can be unlocked with intuitive tools that impact learning curve and process time
    • Low-code / No-code approach to study build can offer complex study builds without reliance on complex or proprietary programming languages
    • Sharing key documentation can further improve efficiency across clinical staff and subjects such as signature collection, patient engagement and digital incentives that lead to improved adherence rates

    Speakers

    Lina Gaggi
    Product Manager, Viedoc

    12 PM

    Implementing decentralised clinical trial (DCT) elements: a sponsor experience

    • Reviewing current state and future direction of decentralized clinical trials post-COVID-19 through sponsor survey results
    • Providing greater understanding of innovative modern solutions that could help support more effective patient engagement and choice
    • Discussing best practices and barriers experienced when implementing DCT elements as part of global trials
    • Sharing learnings to inform of modern patient centric ways of working for industry and regulators and available tools to support this

    Speakers

    Joachim Lovin
    DCT Specialist, Novo Nordisk

    12:30 PM

    Lunch and networking

    1:30 PM

    PI overview of patient safety when carrying out digital elements and decentralized clinical trials

    • Outlining role of the Principal Investigator in digital and decentralized clinical trials
    • Considering key strategies for ensuring patient safety and maintaining regulatory compliance
    • Sharing examples of benefits and challenges of digital integration

    Speakers

    John Zibert
    Chief Medical Officer, Coegin Pharma

    2 PM

    Fireside Chat: How to de-risk a clinical development program?

    • Value of obtaining early feedback from Key Opinion Leaders and Regulators
    • Risk assessment at the trial level
    • Trial oversight matrix implemented with all vendors and subcontractors

    Speakers

    Anna Polak-Andersen
    Head of Clinical Development, Entero Target

    2:30 PM

    Afternoon refreshments, networking and prize draw

    3 PM

    ROUNDTABLE SESSIONS

    During the roundtable discussion session, the conference hall will be divided into zones. Delegates can choose which zone they would like to join. Each zone will be led by a table moderator and will focus on a different challenge within the industry. After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

    Roundtable 1
    Mitigating risk in clinical supply chain
    Pernille Hemmingsen, Chief Technology Officer, Adcendo

    Roundtable 2
    Engaging with CROs: defining deliverables and agreements
    Asger Dahlgaard, VP of Quality Assurance and Regulatory Affairs, BioPorto Diagnostics A/S

    Roundtable 3
    Considering DCT trial design and impact on both the patient and company
    John Zibert, Chief Medical Officer, Coegin Pharma

    Speakers

    Pernille Hemmingsen
    Chief Technology Officer, Adcendo
    Asger Dahlgaard
    VP of Quality Assurance and Regulatory Affairs, BioPorto Diagnostics A/S
    John Zibert
    Chief Medical Officer, Coegin Pharma

    4 PM

    End of conference

    8:45 AM

    Chairperson’s opening remarks

    Speakers

    Libbi Rickenbacher
    Senior Director Product Strategy and Partnerships, 4G Clinical

    9 AM

    Case Study: Real world example of Artificial Intelligence in clinical development – PoC to Production

    • Understanding regulation and preparing compliance
    • Driving innovation and technology into processes through use of generative AI
    • Implementing AI for practical use with valuable return on investment

    Speakers

    Stephen Lutsch
    Senior Director Clinical Trial Digital Innovation, Genmab

    9:30 AM

    AI in Risk Based (Quality) Monitoring

    Regulatory bodies are promoting Risk Based (Quality) Monitoring as a best practice in clinical trials to correct data quality issues as early as possible in the trial lifecycle. Since this involves the identification of specific patterns in large datasets, artificial intelligence can support us in doing this efficiently.

    • How can AI find specific patterns that humans might miss
    • Interactions between AI and humans in RB(Q)M
    • Real life examples in respiratory

    Speakers

    Benoit Cuyvers
    Upstream AI Product Manager, Clario

    10 AM

    Case Study: Accelerating innovation through digital health technology solutions

    • Driving true benefits for clinical research through digital health technology
    • Learnings from barriers created by integration of digital health
    • Improving processes and focusing on delivering digital health as a tool

    Speakers

    Magnus Jörntén-Karlsson
    Head of Digital Patient & Site Technology, Evinova at AstraZeneca

    10:30 AM

    Morning Refreshments & Networking

    11 AM

    Expert Conversation: Strategic Considerations for End-to-End Development of Fit-For-Purpose Digital Measures of Health

    • Strategies for sourcing components from a scattered ecosystem
    • How to develop meaningful, human-centric measures
    • Pitfalls and opportunities for analytical and clinical validation
    • Novel solutions and digital pathways for scalable regulatory qualification
    • Maximizing value: how to repurpose and extend solutions across use cases in R&D and healthcare

    Speakers

    Kai Langel
    CEO, DEEP Measures
    Teske Valk
    Lead Medical Project Manager, Novo Nordisk

    11:30 AM

    The new age of R&D procurement: clinical business operations transformed

    • We will examine the high cost of doing nothing
    • What is the status quo and can technology help?
    • Vendor management - tackling one of the biggest challenges
    • The role that AI can play
    • What you can gain by embracing technology

    Speakers

    Anca Copaescu
    Chief Executive Officer, Strategikon Pharma

    12 PM

    Transforming clinical trials: ideas from leading industry professionals

    • Assessing outcomes from over 70 interviews with life science industry pioneers
    • Reviewing what clinical professionals wish would be different in the life sciences industry
    • Suggesting next steps towards further evolving clinical trials

    Speakers

    Ivanna Rosendal
    Senior Director, IT Business Partner, Ascendis Pharma

    12:30 PM

    Lunch and networking

    1:30 PM

    Maintaining control and oversight of data in outsourced trials

    • Considering, generally and specifically, data collected with eDiary, CGM and other external sources
    • Assessing risks when outsourcing trials
    • Acting accordingly to manage and mitigate risks
    • Maintaining right level of oversight

    Speakers

    Ane Jensen
    Principal Data Manager, Zealand Pharma

    2 PM

    Panel Discussion: Considering existing and emerging technology to assist with clinical trials

    • Digitalization: what can we digitalize to improve systems and processes
    • AI: what can we implement to save time and resource
    • Systems: what technology and systems are available and emerging to assist in clinical trials and data management

     

    Speakers

    Libbi Rickenbacher
    Senior Director Product Strategy and Partnerships, 4G Clinical
    Stephen Lutsch
    Senior Director Clinical Trial Digital Innovation, Genmab
    Ane Jensen
    Principal Data Manager, Zealand Pharma
    Richard Gray
    Managing Partner, Medidata, Dassault Systemes

    2:30 PM

    Afternoon refreshments, networking and prize draw

    10 AM

    Protocol optimization: How a transformational relationship with your CRO can increase your development programs’ chances of success

    • Maximizing the opportunity for strategic input and design feedback from your CRO throughout the outsourcing process
    • Overview of the typical areas where your CRO can guide and facilitate study optimization
    • Examples of where CRO experience has transformed study design and operations, to sponsor advantage

    Speakers

    Rich Bennett
    Senior Director, Therapeutic Strategy Lead, Neuroscience, Worldwide Clinical Trials

    10:30 AM

    Morning Refreshments & Networking

    11 AM

    Building CRO Relationships: What are the critical factors to consider when procuring from a CRO?

    • Establishing common ground with your CRO
    • Ascertaining the critical factors to think about when you collaborate with a CRO
    • Exploring how the concept of co-development between Pharma & CRO is working best
    • Overcoming the differences between Pharma & CRO business models to work in harmony
    • Underlining the factors which could be limiting what choice you make?

    Speakers

    Stine Friis Thorsen
    Project Director, Evaxion Biotech

    11:30 AM

    Why so slow? Insider insights from the clinic floor to speed up the startup and execution of proof-of-concept patient trials

    How to:

    • Harness regulatory dynamics for strategic advantages.
    • Obtain feasibility figures true to delivery.
    • Employ innovative study designs to expedite the development program.
    • Customize efficient patient recruitment tactics!

    Speakers

    Dr. Claudia Hesselmann
    Founder & CEO, ARENSIA Exploratory Medicine

    12 PM

    Panel Discussion: Defining effective governance structures and oversight models

    • Creating an efficient governance structure to suit the study
    • Communicating and monitoring the framework
    • Evaluating needs and wants of both sponsor and vendor companies
    • Sharing best practice for governance oversight

    Speakers

    Helen Johansen Blanco
    Chief Operating Officer, Node Pharma A/S
    Caroline Sandstroem
    Head of Global Clinical Quality, Ferring Pharmaceuticals
    Anna Polak-Andersen
    Head of Clinical Development, Entero Target
    Lien Verheggen
    Head of Clinical Operations. Estetra (a wholly owned subsidiary of Gedeon Richter Plc)
    Sara Thuresson
    Head of Clinical Operations, Guard Therapeutics

    12:30 PM

    Lessons in chemistry: The art of site engagement

    Clinical trials follow a formula, but their success is about more than science. How can sponsors maximise their communications opportunities to stimulate and maintain the passion and proactivity that are key to the success of their study, among site staff with competing priorities, who may feel they’ve seen it all before

    Speakers

    Chloe Gower-Page
    Senior Account Director, Site Engagement, Clinical Trial Experience, Langland

    1 PM

    Lunch and networking

    2 PM

    Clinical trial outsourcing: a customer perspective

    • Clinical trial outsourcing strategies
    • Sponsor company expectations and CRO selection
    • Clinical trial oversight – considerations for finding the right balance between efficiency and safety

    Speakers

    Christopher Burton
    Chief Medical Officer, Reponex Pharmaceuticals A/S

    2:30 PM

    Ensuring success: Essential sponsor oversight strategies for confirming your clinical study is on track

    • Why it is so important to have proper oversight over study conduct
    • How to make it smooth and effective
    • Which aspects of the trial should have your special attention
    • How CRO can support with keeping oversight on the proper level

    Speakers

    Monika Martyka
    Director Clinical Operations, TFS HealthScience

    3 PM

    Clinical Trial Investigations: Looking at the trends and landscape for 2023 and what we can learn from them

    • Overview of global clinical trials for 2023
    • Assessing key sponsors, top interventions and looking at the trial landscape for 2023
    • Looking at key obstacles for terminated trials and evaluation of completed trials which have achieved endpoint status

    Speakers

    Priya Ravisekara
    Senior Analyst, GlobalData

    3:30 PM

    Afternoon refreshments and networking

    4 PM

    Developing neuroimaging and CNS drug: preparing for clinical trial

    • Sharing insights on collaborations with clinical CROs on previous clinical studies
    • Preparing for a clinical trial with a University Hospital in Denmark
    • Choosing and developing the right trial design

    Speakers

    Christine Ryan
    Chief Operating Officer, Gabather

    4:30 PM

    Empowering patients to overcome challenges in orphan drug development

    • Orphan drug market: Illustrate the unique challenges of developing a drug for rare diseases
    • Patient-focused drug development: Designing patient-centered clinical trials
    • Operational considerations: Endpoint selection; reducing the burden of participation; cost; sites; patient concierge services
    • Collaboration: Focus on the need for collaboration in this space: sponsors, CRO (Clinical Research Organizations), patients, patient advocacy groups, investigators, vendors

    Speakers

    Scott Schliebner
    Vice President Drug Development Consulting, Novotech

    5 PM

    Panel Discussion: Focusing on the patient: diversity, engagement and safety

    • Increasing patient engagement and involvement
    • Improving diversity in clinical trials
    • Considering sites and patient safety

    Speakers

    Helen Johansen Blanco
    Chief Operating Officer, Node Pharma A/S
    Révérien Uwacu
    Clinical Trial Supply Expert
    Dr. Claudia Hesselmann
    Founder & CEO, ARENSIA Exploratory Medicine
    John Zibert
    Chief Medical Officer, Coegin Pharma

    5:30 PM

    Chairperson’s closing remarks

    Speakers

    Helen Johansen Blanco
    Chief Operating Officer, Node Pharma A/S

    END OF DAY 1 AND NETWORKING DRINKS SPONSORED BY FORTREA

    2024 Speakers

    Select a speaker to learn more

    Back
    Ivanna Rosendal
    Senior Director, IT Business Partner, Ascendis Pharma

    Session Details:

    Transforming clinical trials: ideas from leading industry professionals

    2024-10-02, 12:00 PM

    View In Agenda

    Social Links:

    Next speaker
    Back
    Magnus Jörntén-Karlsson
    Head of Digital Patient & Site Technology, Evinova at AstraZeneca

    Session Details:

    Case Study: Accelerating innovation through digital health technology solutions

    2024-10-02, 10:00 AM

    View In Agenda
    Next speaker
    Back
    Rikke Winther
    Outsourcing Specialist, Camurus AB

    Rikke Winther has worked in the CRO and Pharmaceutical industry for the past 30 years and has experience from Clinical R&D, Business Development and Contract/Outsourcing Management. She built up and headed up Lundbeck group of Outsourcing & Contracts Management R&D for 19 years and has for the past 5 years worked as an clinical outsourcing specialist for smaller biopharma and covers CRO selection processes as well as contractual, operational and relationship related activities with clinical CROs.

    She has in earlier part of her career within bio-analytical research and clinical development in hospital settings as well as project management and business development management at a clinical CRO in Europe and Asia.

    Rikke is a former member of the Steering Committee member of the Pharmaceutical Contract Management Group (PCMG) for many years and is a contributing author of the book: “Outsourcing Clinical Development, Gower Publishing Limited”.

     

    Session Details:

    Building an Outsourcing Strategy for your clinical trials

    2024-10-01, 9:30 AM

    View In Agenda
    Next speaker
    Back
    John Zibert
    Chief Medical Officer, Coegin Pharma

    Dr. John Zibert, Chief Medical Officer Coegin Pharma AB, a listed Nordic biotech company with several unique molecular technologies and compounds , where he also serves as CEO of Avexxin Oncology AS and Board Member of Reccura Therapeutics AS. He received his master's in medicine and human biology, and PhD in immunology at the University of Copenhagen, DK and University of Otago, NZ. He has demonstrated a successful history of working in the pharmaceutical and digital healthcare industry in established corporate businesses, and in an incubator co-establishing more than 25 start-ups within digital health and biotech, and several of his own biotech companies. Furthermore, he has an academic footprint of 79 publications in particular within digital health, tumor biology and dermatology. He has a deep experience within execution of drug research and development, Decentralized Clinical Trials, digital healthcare solutions, and leadership.

    Session Details:

    Panel Discussion: Focusing on the patient: diversity, engagement and safety

    2024-10-01, 5:00 PM

    Session Details:

    ROUNDTABLE SESSIONS

    2024-10-02, 3:00 PM

    Session Details:

    PI overview of patient safety when carrying out digital elements and decentralized clinical trials

    2024-10-02, 1:30 PM

    View In Agenda
    Next speaker
    Back
    Lene Grejs Petersen
    Senior Advisor, Danish Medicines Agency

    Lene Grejs Petersen is Senior Adviser at the Danish Medicines Agency, Clinical Trial Unit. Lene is member of the Clinical Trials Coordinating and Facilitation Group (CTCG) member since 2008 and is the Danish representative Clinical Trials Advisory Group (CTAG) since 2022. Lene has been an employee at the Danish Medicines Agency since 2000 and she has been involved in the implementation of the EU Clinical Trials Regulation and works as a regulatory assessor and coordinator of clinical trials. Lene has a background as Master in Pharmacy.

    Session Details:

    Sharing latest updates to the Clinical Trial Regulation (CTR) and Clinical Trial Information System (CTIS)

    2024-10-01, 8:30 AM

    View In Agenda
    Next speaker
    Back
    Ditte Zerlang Andersen
    Senior EU Project Lead, Senior Adviser, Danish Medicines Agency

    Ditte Zerlang Andersen joined the Danish Medicines Agency (DKMA) in 2015 as a clinical trial assessor. She now leads strategic projects in our national and EU regulatory landscape as a senior strategy project lead. Ditte recently led the work of the EU ‘COMBINE’ project analysing the interface between clinical trials and the device and in vitro diagnostic area. Prior joining DKMA, Ditte worked 5 years in the pharmaceutical industry and have a PhD in neuroscience.

    Session Details:

    Navigating through the jungle of regulatory requirements for combination trials

    2024-10-02, 9:00 AM

    View In Agenda
    Next speaker
    Back
    Caroline Sandstroem
    Head of Global Clinical Quality, Ferring Pharmaceuticals

    Dr. Caroline Sandström received her PhD in Medical Science from Lund University, Sweden in 2008. She has then worked for Novo Nordisk A/S, Denmark for several years as a pharmacologist driving and executing pharmacological plans supporting pre-clinical projects.

    Her interest and enthusiasm for project management, continuous improvement, streamlining initiatives and training was then later beneficially used when she moved into the compliance area managing global improvement and training initiatives within R&D Quality Management System (QMS) including Clinical. For example, she was the project manager for implementing the effective use of Root Cause Analysis in Clinical Development activities but also being highly involved in initiatives related to Quality Culture.  Ferring Pharmaceuticals A/S in Copenhagen, DK. On a daily basis she was involved in discussing, driving compliance and improvement initiatives within both Non-Clinical, Clinical and Pharmacovigilance related activities. She has taken a very active role in contributing to a collaborative and transparent organization where sharing learnings are a main focus area.

    From beginning of May 2022, she moved into the position of being Head of the Global Clinical Quality Department being responsible for the QA support of global key stakeholder areas such as Clinical Development, Regulatory Affairs, Pharmacovigilance and Discovery. Her scientifically driven problem-solving skills are used for implementing global cross-functional initiatives, and for supporting and strengthening the harmonization and quality mindset in the organization.

    Session Details:

    Panel Discussion: Defining effective governance structures and oversight models

    2024-10-01, 12:00 PM

    View In Agenda
    Next speaker
    Back
    Christine Ryan
    Chief Operating Officer, Gabather

    Dr Christine Natasha Ryan holds a PhD in Neuroscience from the University of Cambridge, Cambridge, UK and an MBA from Stockholm School of Economics. Following a post-doc at the Brain Research Institute, St. Hans Hospital, Roskilde, Denmark, Dr Ryan remained in Scandinavia moving to Sweden to work at Astra, which then became AstraZeneca, holding line management and competitive intelligence roles. Dr Ryan has engaged in preclinical research at blue chip companies such as AstraZeneca, smaller pharmaceutical companies, CROs and biotechs, working at Karo Bio AB, and Cerca Insights among others. Dr Ryan joined Gabather AB as Principal Scientist in 2017, becoming VP Operations in 2018. She is currently COO.

    Session Details:

    Developing neuroimaging and CNS drug: preparing for clinical trial

    2024-10-01, 4:00 PM

    View In Agenda
    Next speaker
    Back
    Stephen Lutsch
    Senior Director Clinical Trial Digital Innovation, Genmab

    In my position as Senior Director - Clinical Trial Digital Innovation at Genmab, I lead a team driving AI adoption within clinical operations, decentralized clinical trials and digital innovation in drug development. Previously, I have been working to bring the best disruptive innovation into normal clinical operations at LEO Pharma to help improve and accelerate their clinical trials. Furthermore, I am trying to solve some of the toughest challenges related to scaling digitalization, data, and automation to generate competitive advantages across business units. One aspect is driving the necessary foundational components around a scalable GxP data platform, machine learning opportunities as well as automating digital processes with robotics process automation. Besides leading the necessary change internally, focus is on a design-thinking approach where we put the patient and site at the center. I have an ambition towards “delighting” patients, investigators, and sponsors by solving the real-world challenges they face by leveraging both qualitative interviews and observation, as well as quantitative methods to reveal actionable insights

    Session Details:

    Case Study: Real world example of Artificial Intelligence in clinical development – PoC to Production

    2024-10-02, 9:00 AM

    Session Details:

    Panel Discussion: Considering existing and emerging technology to assist with clinical trials

    2024-10-02, 2:00 PM

    View In Agenda
    Next speaker
    Back
    Priya Ravisekara
    Senior Analyst, GlobalData

    Priya Ravisekara, MSc,is a senior analyst at GlobalData in London, UK, where her primary responsibilities include producing analytical reports, improving and maintaining database functionality through quality assurance testing, updating and monitoring Global Data’s Clinical Trials Intelligence Database, and answering queries directly from clients. Priya holds a Masters in Clinical Drug Development from Barts and The London School of Medicine and Dentistry, and a Bachelor of Science in Biochemistry from Brunel University, London.​

    Session Details:

    Clinical Trial Investigations: Looking at the trends and landscape for 2023 and what we can learn from them

    2024-10-01, 3:00 PM

    View In Agenda
    Next speaker
    Back
    Morten Pedersen
    VP, Head of Clinical Operations, Lundbeck

    Morten completed his Master’s degree in Biotechnology at National University of Ireland, Galway, in 1997, specializing in Pharmacology. He joined Lundbeck in August 2020 as VP, Head of Clinical Operations.

    Career to date Morten started at a CRO in 1997 as a CRA on an Epilepsy study.  In the subsequent years he worked in CRO’s, consultancy and big Pharma taking on roles within Project Management, Program Oversight, Innovation and Strategic Partnerships.  He joined Pfizer in 2003 and has a wide range of project management experience delivering projects across multiple therapeutic areas. From 2007 to 2011 he held a leadership role in Pfizer’s Clinical Study Management group providing Operational Oversight in various outsourcing models.  As Group Lead of Emerging Markets and Established Products Business Units he managed a team of Program Directors in a variety of Therapy Areas from Phase II to Late Phase and Non-Interventional trials. From late 2011 Morten joined an Innovation technology CRO in the role of Senior Director and Head of Strategic Partnerships with the aim of improving Clinical Trial efficiencies and supporting Trial Sites. In August 2016 he joined InVentiv Health as VP, Head of Program Delivery in Neuroscience, before the group merged with INC to become Syneos Health.

     

    Session Details:

    Improving sustainability: Healthcare transition into a Net Zero world

    2024-10-02, 10:00 AM

    View In Agenda
    Next speaker
    Back
    Helen Johansen Blanco
    Chief Operating Officer, Node Pharma A/S

    Helén Johansen Blanco has 24 years of clinical development experience, managing Phase I to III clinical trials leading to the successful launch of several oncology products, as Revlimid, Xofigo and a Herceptin biosimilar. She has experience in project management and financial oversight of large global clinical trials conducted in all continents of the world, mainly within oncology, but also therapeutic areas as cardiovascular and gastrointestinal. Mrs. Blanco has previously worked for large international pharma companies such as AstraZeneca and Mylan, as well as small, medium to large sized biotechnology companies as Nordic Nanovector, Oncoinvent, Cantargia, Cytovation and Celgene. Currently she holds a position as Chief Operating Officer at Node Pharma AS, a small medium sized Norwegian biotech company. She holds a Diploma Engineer/MSc degree in Biophysics and medical technology and a MBA.

    Session Details:

    Chairperson’s Opening Remarks

    2024-10-02, 8:45 AM

    Session Details:

    Panel Discussion: Focusing on the patient: diversity, engagement and safety

    2024-10-01, 5:00 PM

    Session Details:

    Chairperson’s closing remarks

    2024-10-01, 5:30 PM

    Session Details:

    Re-evaluating your study if things go wrong in clinical trial: to stay or change?

    2024-10-02, 11:00 AM

    Session Details:

    Panel Discussion: Defining effective governance structures and oversight models

    2024-10-01, 12:00 PM

    View In Agenda
    Next speaker
    Back
    Christopher Burton
    Chief Medical Officer, Reponex Pharmaceuticals A/S

    Session Details:

    Clinical trial outsourcing: a customer perspective

    2024-10-01, 2:00 PM

    View In Agenda
    Next speaker
    Back
    Ane Jensen
    Principal Data Manager, Zealand Pharma

    Ane H. Jensen (MA)

    Passionate about new technology and their ability to change the way we conduct clinical trials. Has worked at different positions in Novo Nordisk between 2008 and 2020. Since 2020 employed at Zealand Pharma. Previous experiences include RTSM, training, process improvements, logistics, clinical trials supplies and eLearning development.

    Session Details:

    Maintaining control and oversight of data in outsourced trials

    2024-10-02, 1:30 PM

    Session Details:

    Panel Discussion: Considering existing and emerging technology to assist with clinical trials

    2024-10-02, 2:00 PM

    View In Agenda
    Next speaker
    Back
    Anna Polak-Andersen
    Head of Clinical Development, Entero Target

    Session Details:

    Panel Discussion: Defining effective governance structures and oversight models

    2024-10-01, 12:00 PM

    Session Details:

    Fireside Chat: How to de-risk a clinical development program?

    2024-10-02, 2:00 PM

    View In Agenda
    Next speaker
    Back
    Dr. Claudia Hesselmann
    Founder & CEO, ARENSIA Exploratory Medicine

    Dr. Claudia Hesselmann, a chemist by training, with a PhD in molecular biology. Claudia has twenty years of expertise in the early phases of drug development. Her experience includes co-founding and holding management positions in various CROs. Her extensive background and social acumen, along with her first-hand knowledge of the industry, led Claudia to co-found ARENSIA Exploratory Medicine in Düsseldorf, Germany. Her primary aim is the contribution of innovative approaches to bring about substantial acceleration to the drug development process and enable more agile patient access to novel therapeutics.

     

    Session Details:

    Panel Discussion: Focusing on the patient: diversity, engagement and safety

    2024-10-01, 5:00 PM

    Session Details:

    Why so slow? Insider insights from the clinic floor to speed up the startup and execution of proof-of-concept patient trials

    2024-10-01, 11:30 AM

    View In Agenda
    Next speaker
    Back
    Lien Verheggen
    Head of Clinical Operations. Estetra (a wholly owned subsidiary of Gedeon Richter Plc)

    Session Details:

    Panel Discussion: Defining effective governance structures and oversight models

    2024-10-01, 12:00 PM

    View In Agenda
    Next speaker
    Back
    Sara Thuresson
    Head of Clinical Operations, Guard Therapeutics

    Session Details:

    Panel Discussion: Defining effective governance structures and oversight models

    2024-10-01, 12:00 PM

    View In Agenda
    Next speaker
    Back
    Joachim Lovin
    DCT Specialist, Novo Nordisk

    Joachim Lövin has worked in the pharmaceutical industry for over 20 years across various therapeutic areas and organizations. During this time, Joachim has worked in different roles spanning over Data Management, Project Management, Process Development, Senior Business Analyst and Clinical Operations. In his current role as DCT Specialist, Joachim focuses on supporting trials including competence development of Clinical Operations, identifying opportunities, and operationalising Decentralised Clinical Trial Elements across Novo Nordisk. Joachim is the Workstream Lead for the Modernizing Clinical Trial Conduct workstream for TransCelerate Biopharma, and a member of the eClinical Forums Trial of the Future. All of Joachim’s work is aligned with his passion to improve patient experience and accelerating clinical trials.

    Session Details:

    Implementing decentralised clinical trial (DCT) elements: a sponsor experience

    2024-10-02, 12:00 PM

    View In Agenda
    Next speaker
    Back
    Anca Copaescu
    Chief Executive Officer, Strategikon Pharma

    Anca Copaescu, our CEO, is the powerhouse behind Strategikon's success and the driving force behind the company's revolutionary Clinical Maestro® platform.

    With over 15 years of experience in the clinical research industry, Anca's expertise in clinical outsourcing and analytics is second to none. As Head of Clinical Outsourcing and Analytics at BioMarin Pharmaceuticals, she managed and advanced the company's global outsourcing, vendor management and clinical analytics functions.

    Her passion for efficiency and innovation led her to relentlessly pursue improvements in clinical study planning, outsourcing, and financial management. And when she couldn't find a technology solution that met her standards, she decided to build a better one - the game-changing Clinical Maestro platform.

    Session Details:

    The new age of R&D procurement: clinical business operations transformed

    2024-10-02, 11:30 AM

    View In Agenda
    Next speaker
    Back
    Kento Nakamura
    Strategy and Corporate Development, CMIC

    Kento Nakamura is a global professional having worked both in the Western and Eastern healthcare landscapes. He has been in various roles, contributing significantly to drug development, market access, and pharmaceutical marketing.

    At CMIC, Japan and South Korea’s first CRO, Kento wears multiple hats including helping formulate corporate strategy, creating mutually beneficial partnerships with other companies, and taking initiative to create business development opportunities.

    During his tenure at KM Pharmaceutical Consulting, a boutique drug development consulting firm, Kento co-pioneered the market access perspective on drug development, resulting in key additional endpoints in an ongoing phase 2 study. He also played a crucial role in developing the global drug safety plan, ensuring compliance with reporting requirements across multiple continents.

    Kento holds an MPH in Health Management from Harvard University and a BS in Biology from Tufts University. He is fluent in English and proficient in Japanese. In his free time, Kento enjoys playing tennis, watching football, visiting contemporary art museums, and traveling around the world.

    Session Details:

    Asia Pacific clinical trials: opportunities and regulatory updates

    2024-10-02, 9:30 AM

    View In Agenda
    Next speaker
    Back
    Asger Dahlgaard
    VP of Quality Assurance and Regulatory Affairs, BioPorto Diagnostics A/S

    Session Details:

    ROUNDTABLE SESSIONS

    2024-10-02, 3:00 PM

    View In Agenda
    Next speaker
    Back
    Scott Schliebner
    Vice President Drug Development Consulting, Novotech

    Scott is a strategic and innovative drug development executive with 30 years experience across the biopharma, CRO, and non-profit sectors.  Passionate about ensuring the patient voice is incorporated into drug development, Scott is focused on patient-focused innovations that reduce the burden of clinical trial.  With a particular focus on rare diseases, Scott has built partnerships and collaborations that have led to the acceleration of drug development for rare disease patients.  He received a Master’s Degree in Public Health in Biostatistics from the University of Utah School of Medicine and completed a Graduate Research Fellowship at The National Institutes of Health/NINDS.

    Session Details:

    Empowering patients to overcome challenges in orphan drug development

    2024-10-01, 4:30 PM

    View In Agenda
    Next speaker
    Back
    Teske Valk
    Lead Medical Project Manager, Novo Nordisk

    Session Details:

    Expert Conversation: Strategic Considerations for End-to-End Development of Fit-For-Purpose Digital Measures of Health

    2024-10-02, 11:00 AM

    View In Agenda
    Next speaker
    Back
    Kai Langel
    CEO, DEEP Measures

    Session Details:

    Expert Conversation: Strategic Considerations for End-to-End Development of Fit-For-Purpose Digital Measures of Health

    2024-10-02, 11:00 AM

    View In Agenda
    Next speaker
    Back
    Rich Bennett
    Senior Director, Therapeutic Strategy Lead, Neuroscience, Worldwide Clinical Trials

    Richard Bennett is Senior Director and Therapeutic Strategy Lead in the Neuroscience franchise at Worldwide Clinical Trials. With two decades in the industry, he has advanced through the traditional clinical operations roles such as clinical research associate and clinical trial manager and has spent many years as a leader of clinical development programs in both the larger pharma and biotech setting. He has worked on neuromuscular disorders, rare diseases, critical care, pain and palliative care, dermatology, and epidemiology programs. His direct experience working with large pharma and small and emerging biotech firms has given him a deep understanding of the needs of our sponsors

    Session Details:

    Protocol optimization: How a transformational relationship with your CRO can increase your development programs’ chances of success

    2024-10-01, 10:00 AM

    View In Agenda
    Next speaker
    Back
    Richard Gray
    Managing Partner, Medidata, Dassault Systemes

    Richard Gray is a Managing Partner at Dassault Life Sciences, engaged across the full portfolio including the market leading Medidata brand. He has been serving the life sciences & healthcare industry for over 30 years, inspired by the opportunity to accelerate productivity across the value chain and improve outcomes for patients.

    With a background in process optimization, data, and technology, he has enabled many European and US sponsors to uplift their capabilities, and in his current role he is driving innovation in areas including early-stage research and discovery, through preclinical and clinical, out to manufacturing, supply chain and commercialisation.

    Richard believes that data [strategy] holds the key to accelerating the value of technology, creating the opportunity to connect physical and digital worlds to advance virtual twin experiences, enabling the promise of AI to be democratized, and fueling in silico approaches that will revolutionise the science of tomorrow.

    Session Details:

    A new paradigm for clinical innovation

    2024-10-01, 9:00 AM

    Session Details:

    Panel Discussion: Considering existing and emerging technology to assist with clinical trials

    2024-10-02, 2:00 PM

    View In Agenda
    Next speaker
    Back
    Monika Martyka
    Director Clinical Operations, TFS HealthScience

    Monika Martyka has over 14 years of experience in clinical research and currently serves as Director of Clinical Operations at TFS HealthScience. She leads complex clinical projects, overseeing cross-functional teams, optimizing clinical processes, and ensuring alignment with regulatory standards. Monika excels in managing the intricacies of clinical trials, including protocol development, patient recruitment, and compliance, while driving operational efficiency to meet critical milestones.

    Her expertise in both clinical and operational management has made her a key player in advancing healthcare through rigorous research methodologies. Dedicated to fostering collaboration and innovation, Monika is committed to the successful delivery of high-impact clinical trials that contribute to the development of cutting-edge therapies and improve patient outcomes globally.

    Session Details:

    Ensuring success: Essential sponsor oversight strategies for confirming your clinical study is on track

    2024-10-01, 2:30 PM

    View In Agenda
    Next speaker
    Back
    Lina Gaggi
    Product Manager, Viedoc

    Lina Gaggi, Product Manager, has over 10 years' experience in computer engineering developing and delivering the products that customers want. With a keen eye for user needs, she knows how to find the right solution that reduces complexity and makes software enjoyable. Focusing on the life science industry at this stage in her career, she’s a dedicated product manager that can distill the big picture in order to find robust solutions for small tasks, that in the end deliver value to customers.

    Session Details:

    Reimagining clinical trials: Boosting efficiency with simplified, low-code builds

    2024-10-02, 11:30 AM

    View In Agenda
    Next speaker
    Back
    Stine Friis Thorsen
    Project Director, Evaxion Biotech

    Session Details:

    Building CRO Relationships: What are the critical factors to consider when procuring from a CRO?

    2024-10-01, 11:00 AM

    View In Agenda
    Next speaker
    Back
    Benoit Cuyvers
    Upstream AI Product Manager, Clario

    Benoit Cuyvers is the Upstream AI (Artificial Intelligence) Product Manager for Clario, recently joining the team from the ArtiQ acquisition. (Leuven, Belgium). The acquisition advances our respiratory solutions portfolio, combining Clario’s deep scientific expertise with ArtiQ’s innovative artificial intelligence capabilities. Benoit led the efforts on the ArtiQ AI-enabled Risk Based Monitoring system, from concept to solution and will continue these endeavors in his role at Clario. With his background in Bioscience Engineering and his past experience as a digital health expert at Siemens, Benoit is able to apply learnings from other medical and technical fields to the field of AI in respiratory research & medicine.

    Session Details:

    AI in Risk Based (Quality) Monitoring

    2024-10-02, 9:30 AM

    View In Agenda
    Next speaker
    Back
    Chloe Gower-Page
    Senior Account Director, Site Engagement, Clinical Trial Experience, Langland

    Chloe has spent the last 10 years working within healthcare communications, gaining experience across advertising, medical strategy and education and clinical trials. Her experience spans the full product lifecycle, from protocol review and early phase clinical trials through product launch and then lifecycle management. Through this she has worked with a broad stakeholder group including marketing, medical affairs, clinical development and operations, market access and field force teams, as well as with small, medium and big pharma.

    Chloe is a strategic thinker and loves partnering closely with her clients to really understand their challenge. She is skilled at bringing in the right expertise at the right time to enable her clients to think further about the work they are doing, innovate when needed and ultimately deliver for the best outcomes for patients. In her current role, Chloe provides strategic leadership to her clients across a range of site engagement activities, from standalone IMs through to broader strategic communication planning for sites. She is passionate about creating programmes that allow true collaboration between site and sponsor, enabling studies to perform well and build relationships that last beyond the end of a single study.

    Chloe has worked across a number of therapy areas with extensive experience in rare disease, oncology, ophthalmology and gastroenterology. Prior to working within healthcare communications, Chloe gained a degree in Human Biology from the University of Birmingham and further training in Human Nutrition.

    Session Details:

    Lessons in chemistry: The art of site engagement

    2024-10-01, 12:30 PM

    View In Agenda
    Next speaker
    Back
    Révérien Uwacu
    Clinical Trial Supply Expert

    Originally from Rwanda and now based in Belgium, Révérien brings a unique blend of global experience and cultural insight to the clinical trial supply landscape.
    With over 12 years of expertise in pharmaceutical supply chain management, he has successfully collaborated with leading companies such as Johnson & Johnson, Baxter, Thermo Fisher, and UCB.

    Révérien’s academic background in IT and Supply Chain, combined with his deep understanding of clinical trial logistics, positions him as a forward-thinking expert in leveraging technology and innovation to optimize supply chains.
    His focus includes improving trial diversity, enhancing efficiency, and ensuring patient safety through data-driven and patient-centered strategies.
    As a passionate advocate for advancing clinical trials in underserved regions, Révérien is dedicated to addressing logistical challenges and fostering inclusivity in clinical research globally

    Session Details:

    Panel Discussion: Focusing on the patient: diversity, engagement and safety

    2024-10-01, 5:00 PM

    View In Agenda
    Next speaker
    Back
    Pernille Hemmingsen
    Chief Technology Officer, Adcendo

    Pernille Hemmingsen has more than a decade of experience in the development of pharmaceutical products. With a background in biophysical chemistry and chemical engineering, she is particularly interested in the development of robust manufacturing methods and solid quality to enable the best patient experience and convenience. This interest has led to the development of products ranging from cancer targeting liposomes and antibody drug conjugates to tamper resistant tablets and enhanced diabetes formulations at companies including Genmab and Novo Nordisk. Currently, Pernille Hemmingsen is responsible for the chemistry, manufacturing and control at Adcendo, taking to role as CTO. This work particularly includes establishing an efficient supply chain that encompasses elements from both biologics and small molecules. Pernille holds a Ph.D. from the Department of Chemistry at the Technical University of Denmark and an executive Master of Business Administration from Copenhagen Business School.

    Session Details:

    ROUNDTABLE SESSIONS

    2024-10-02, 3:00 PM

    View In Agenda

    OCT Advisory Board

    Select a member to learn more

    Back
    Rosalie Filling
    Vice President, Senior Global Head R&D Operations, Endo Pharmaceuticals

    In her over 25 years of experience, Rosalie “Rosie” Filling has transformed R&D operations in every company she has worked for, developing clear-cut strategies to help advance clinical trials with high-quality operational execution and scientific excellence.

     

    Rosie is the Vice President, Senior Global Head R&D Operations Endo International plc. She is part of the global R&D leadership team and is charged with the coordination and implementation of clinical development strategies for the company’s research and development. She provides strategic direction and oversight of the R&D Operations team, which includes clinical operations, data management, biostatistics, medical writing, clinical supplies, trial master file/inspection readiness and business operations. This integrated team handles the execution of all aspects related to Endo’s clinical trials. Endo has active research and development programs in men’s health, orthopedics, and endocrinology. Beyond these therapeutic areas, the company also has focused development in the areas of sterile injectables and complex generic products.

     

    Rosie’s main focus at all times is on the end users—the patients. Bringing new and, at times, life-saving medications to patients drives Rosie’s sense of purpose.

     

    Rosie joined Endo from Lupin Pharmaceuticals in Blue Bell, PA where she was Senior Director, Head of Clinical Operations, and built the clinical operations organization to support the US and Global R&D Organization. Prior to Lupin, Rosie spent nearly five years at Teva in Frazer, PA where she was the US site head of Clinical Operations and was responsible for the successful delivery of Inhalation, Women’s Health, and Cardiovascular clinical trials. Earlier in her career, Rosie held various roles at Eisai, MGI Pharma and PPD.

     

    Rosie earned her B.S. in Biology with a minor in Chemistry from the University of Pittsburgh.

    Next
    Back
    Kathleen Cohen
    Vice President, Clinical Development, Marinus Pharmaceuticals

    Kathleen Frenia Cohen is Vice President and Head of Clinical Development Operations at Marinus Pharmaceuticals.  Prior to joining Marinus, she spent 20+ years at PRA Health Sciences in a variety of project management and operational oversite roles. Kathleen graduated from the University of the Science in Philadelphia with a PharmD and completed a post-doctoral fellowship in Pharmacoeconomics and Outcomes Research from Rutgers College of Pharmacy. Kathleen resides in Media, PA.

    Next
    Back
    THOMAS M TREMBLAY
    Vice President Of Clinical Development, Trefoil Therapeutics, Inc

    Thomas is a registered nurse with both clinical and over 30 years pharmaceutical development experience. His pharmaceutical development experience includes clinical operations, clinical science, clinical development, drug safety and quality. He is currently Vice President of Clinical Development at Trefoil Therapeutics and adjunct faculty at San Francisco State University.

    Next
    Back
    Behtash Bahador
    Director, Health Literacy, CISCRP

    Behtash Bahador is the Director of Health Literacy at the non-profit organization CISCRP, and holds a Master of Science in Health Communication from the Tufts University School of Medicine. Since 2014, he has collaborated with a range of stakeholder groups to establish and implement patient- and public-centric initiatives across the life-cycle of drug and treatment development. This has included supporting the development of regulatory and cross-disciplinary best practice guidelines, operationalizing key elements of evidence-based public health programing into research engagement activities, and always keeping the needs of patients, participants and the public at the forefront of his work.

    Next
    Back
    Bao Dinh
    Global Development Business Operation, Takeda

    With over 15 years of experience in Clinical Data Management, Bao leads business strategy and vendor operations for Takeda’s Clinical Data Management, Clinical Data Engineering, and Clinical Data Standards groups, driving organizational growth, managing global FSP partnerships, and enhancing cross-functional collaboration. As a member of the 2024–2025 OCT Advisory Board, Bao brings expertise in clinical outsourcing, strategic vendor partnerships, and RFP process optimization, providing a fresh vision for the organization.

    Beyond professional achievements, Bao is dedicated to fostering collaboration and investing in the local community. As a partner of The Town FC and a Silicon Valley angel investor, Bao champions ventures that advance sustainable growth, youth enrichment, and innovation in technology.’

    Plan Your Visit

    Venue

    Clarion Hotel & Congress Copenhagen Airport

    Clarion Hotel & Congress Copenhagen Airport, Kastrup,Denmark, 2770

    Book Your Stay

    Accommodation

    Arena International Events Group “(Arena”) is aware of numerous third party agencies which are contacting Arena’s customers and purporting to have access to hotel room bookings and events attendee lists. For the avoidance of doubt, Arena will only share attendee lists with carefully selected third party partners for event registration purposes. Whilst Arena International Events Group pursues third party agencies for their potentially illicit activity, Arena encourages you to be cautious in engaging with such third party agencies and Arena shall not accept any responsibility for any losses incurred by you should you choose to engage with third parties that have no affiliation to Arena International Events Group.

    Sponsors

    Select a sponsor to learn more

    FEATURED SPONSORS

    SESSION SPONSORS

    TECHNOLOGY SHOWCASE SPONSOR

    DRINKS RECEPTION SPONSOR

    LANYARDS SPONSOR

    EXHIBITORS

    CO SPONSOR

    Why partner?

     

    Contact us to become a partner

    Partnership Opportunities

    We work with you to design a bespoke package to meet your business needs, where you could:

    • Demonstrate your expertise on the agenda – have the attention of the entire audience. For greatest impact, why not position your talk before a networking break and immediately conduct follow up conversations with highly engaged attendees
    • Showcase your business and its services at an exhibition booth, which provides a perfect meeting place for prospective new clients
      Present the value proposition of your offering over your competitors, in front of an audience of active, engaged potential customers
    • Speak with key decision makers as part of our intimate, interactive roundtable style workshop sessions with over 8 hours allowed for networking

    Event reach

    • 200+ attendees each year
    • 80% attendees C-suite level

     

    Take a look at our current sponsors

    Media Centre

    Become A Media Partner

    Enquiry

    Contact Us

    SPONSORSHIP ENQUIRIES

    Alex Purnell

    Senior Sponsorship Manager

    +44 204540 7786

    SPEAKER ENQUIRIES

    Ruth Atterbury

    Portfolio Manager

    +44 (0) 20 4540 7796

    MARKETING ENQUIRIES

    Moona Popal

    Marketing Manager

    DELEGATE ENQUIRIES

    Sunny Saikia

    VIP Delegate Manager

    SPONSORSHIP ENQUIRIES

    To enquire about sponsorship opportunities for the conference, please contact:

    Alex Purnell

    Senior Sponsorship Manager


    +44 204540 7786

    SPEAKER ENQUIRES

    To enquire about speaking opportunities for the conference, please contact:

    Ruth Atterbury

    Portfolio Manager


    +44 (0) 20 4540 7796